These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
818 related articles for article (PubMed ID: 26052395)
1. Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues. Rapti I; Hadziyannis S World J Hepatol; 2015 May; 7(8):1064-73. PubMed ID: 26052395 [TBL] [Abstract][Full Text] [Related]
2. Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma. Chen LP; Zhao J; Du Y; Han YF; Su T; Zhang HW; Cao GW World J Virol; 2012 Dec; 1(6):174-83. PubMed ID: 24175223 [TBL] [Abstract][Full Text] [Related]
3. Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma. Baran B World J Hepatol; 2015 Jul; 7(13):1742-54. PubMed ID: 26167247 [TBL] [Abstract][Full Text] [Related]
4. Time for an active antiviral therapy for hepatitis B: An update on the management of hepatitis B virus infection. Chae HB; Hann HW Ther Clin Risk Manag; 2007 Aug; 3(4):605-12. PubMed ID: 18472982 [TBL] [Abstract][Full Text] [Related]
5. Treatment of chronic hepatitis B virus infection - Dutch national guidelines. Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL; Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260 [TBL] [Abstract][Full Text] [Related]
6. INASL Position Statements on Prevention, Diagnosis and Management of Hepatitis B Virus Infection in India: The Andaman Statements. Arora A; Singh SP; Kumar A; Saraswat VA; Aggarwal R; Bangar M; Bhaumik P; Devarbhavi H; Dhiman RK; Dixit VK; Goel A; Goswami B; Kapoor D; Madan K; Narayan J; Nijhawan S; Pandey G; Rai RR; Sahu MK; Saraf N; Shalimar ; Shenoy T; Thomas V; Wadhawan M; J Clin Exp Hepatol; 2018 Mar; 8(1):58-80. PubMed ID: 29743798 [TBL] [Abstract][Full Text] [Related]
7. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy. Coffin CS; Rezaeeaval M; Pang JX; Alcantara L; Klein P; Burak KW; Myers RP Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1262-9. PubMed ID: 25312649 [TBL] [Abstract][Full Text] [Related]
8. Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients. Hadziyannis SJ Expert Opin Investig Drugs; 2007 Jun; 16(6):777-86. PubMed ID: 17501691 [TBL] [Abstract][Full Text] [Related]
9. Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. Vlachogiannakos J; Papatheodoridis G World J Gastroenterol; 2013 Dec; 19(47):8822-30. PubMed ID: 24379605 [TBL] [Abstract][Full Text] [Related]
10. Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation. Zhang MY; Zhu GQ; Shi KQ; Zheng JN; Cheng Z; Zou ZL; Huang HH; Chen FY; Zheng MH Oncotarget; 2016 May; 7(21):30642-58. PubMed ID: 27121321 [TBL] [Abstract][Full Text] [Related]
11. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. Papatheodoridis GV; Lampertico P; Manolakopoulos S; Lok A J Hepatol; 2010 Aug; 53(2):348-56. PubMed ID: 20483498 [TBL] [Abstract][Full Text] [Related]
12. Entecavir: a new nucleoside analogue for the treatment of chronic hepatitis B. Rivkin A Drugs Today (Barc); 2007 Apr; 43(4):201-20. PubMed ID: 17460784 [TBL] [Abstract][Full Text] [Related]
13. Chronic Hepatitis B Infection: A Review. Tang LSY; Covert E; Wilson E; Kottilil S JAMA; 2018 May; 319(17):1802-1813. PubMed ID: 29715359 [TBL] [Abstract][Full Text] [Related]
14. Prevention of hepatocellular carcinoma: beyond hepatitis B vaccination. Kim MN; Han KH; Ahn SH Semin Oncol; 2015 Apr; 42(2):316-28. PubMed ID: 25843736 [TBL] [Abstract][Full Text] [Related]
15. Role of antiviral therapy in the natural history of hepatitis B virus-related chronic liver disease. Russo FP; Rodríguez-Castro K; Scribano L; Gottardo G; Vanin V; Farinati F World J Hepatol; 2015 May; 7(8):1097-104. PubMed ID: 26052398 [TBL] [Abstract][Full Text] [Related]
16. Hepatocellular Carcinoma and Hepatitis: Advanced Diagnosis and Management with a Focus on the Prevention of Hepatitis B-Related Hepatocellular Carcinoma. Kim SR; Kim SK Diagnostics (Basel); 2023 Oct; 13(20):. PubMed ID: 37892033 [TBL] [Abstract][Full Text] [Related]
17. Treatment of chronic hepatitis B: case selection and duration of therapy. Leung N J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721 [TBL] [Abstract][Full Text] [Related]
18. Effect of Telbivudine Versus Other Nucleos(t)ide Analogs on HBeAg Seroconversion and Other Outcomes in Patients with Chronic Hepatitis B: A Network Meta-Analysis. Liang X; Fan R; Sun J; Shaikh J; Taneja A; Gupta S; Hamed K Adv Ther; 2016 Apr; 33(4):519-31. PubMed ID: 26921204 [TBL] [Abstract][Full Text] [Related]
19. Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis. Zhang MY; Zhu GQ; Zheng JN; Cheng Z; Van Poucke S; Shi KQ; Huang HH; Chen FY; Zheng MH Expert Rev Anti Infect Ther; 2017 May; 15(5):503-513. PubMed ID: 28317397 [TBL] [Abstract][Full Text] [Related]
20. [Oral nucleos(t)ide analogues antiviral therapy reduces HBV-related HCC: consensus and contention]. Han C; Dou XG Zhonghua Gan Zang Bing Za Zhi; 2021 Apr; 29(4):293-296. PubMed ID: 33979951 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]